- Home
- ZIP vs DCTH Comparison
ZIP vs DCTH Comparison
Compare ZIP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- DCTH
- Stock Information
- Founded
- ZIP 2010
- DCTH 1988
- Country
- ZIP United States
- DCTH United States
- Employees
- ZIP N/A
- DCTH N/A
- Industry
- ZIP Diversified Commercial Services
- DCTH Medical/Dental Instruments
- Sector
- ZIP Consumer Discretionary
- DCTH Health Care
- Exchange
- ZIP Nasdaq
- DCTH Nasdaq
- Market Cap
- ZIP 427.4M
- DCTH 388.3M
- IPO Year
- ZIP 2021
- DCTH N/A
- Fundamental
- Price
- ZIP $5.06
- DCTH $10.73
- Analyst Decision
- ZIP Hold
- DCTH Strong Buy
- Analyst Count
- ZIP 4
- DCTH 4
- Target Price
- ZIP $4.75
- DCTH $24.50
- AVG Volume (30 Days)
- ZIP 1.2M
- DCTH 486.2K
- Earning Date
- ZIP 11-05-2025
- DCTH 11-07-2025
- Dividend Yield
- ZIP N/A
- DCTH N/A
- EPS Growth
- ZIP N/A
- DCTH N/A
- EPS
- ZIP N/A
- DCTH 0.06
- Revenue
- ZIP $450,401,000.00
- DCTH $70,240,000.00
- Revenue This Year
- ZIP N/A
- DCTH $159.22
- Revenue Next Year
- ZIP $9.94
- DCTH $41.22
- P/E Ratio
- ZIP N/A
- DCTH $199.29
- Revenue Growth
- ZIP N/A
- DCTH 491.35
- 52 Week Low
- ZIP $3.35
- DCTH $8.08
- 52 Week High
- ZIP $11.25
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ZIP 56.74
- DCTH 44.22
- Support Level
- ZIP $4.59
- DCTH $11.01
- Resistance Level
- ZIP $5.08
- DCTH $11.93
- Average True Range (ATR)
- ZIP 0.26
- DCTH 0.44
- MACD
- ZIP 0.00
- DCTH 0.04
- Stochastic Oscillator
- ZIP 60.51
- DCTH 6.25
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.